Subject has history or evidence of significant neurologic disease other than AD

Subject has a history of stroke

Subject has been treated for schizophrenia or recurrent mood disorder within the previous three years

Subject has a hematologic or solid malignancy diagnosed within five years prior to study entry

Subject has medically unstable COPD or asthma

Subject has end stage CHF (NYHA Class III or IV) or unstable angina

Subject has evidence of significant renal insufficiency

Subject has insulin-dependent diabetes mellitus or HbA1C\>8.5% at screening

A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease